OBJECTIVE: To study the efficacy of symptom relief and the safety of the Dumon Y-stent for central airway obstruction in malignant main carinal involvement and in malignant tracheoesophageal fistulas. DESIGN: A retrospective review. SETTING: Thoracic endoscopy referral center. PATIENTS AND METHODS: The medical records of 86 patients who had undergone the placement of a Dumon Y-stent at our institution were reviewed and analyzed. RESULTS: Ninety Dumon Y-stents were placed in 86 patients to relieve symptoms of dyspnea, cough, and/or hemoptysis. Four of these patients required removal of that stent and replacement with a longer Dumon Y-stent due to tumor progression. There were only two instances of procedure-related adverse effects, which included coughing following stent placement lasting 1 week in one patient and stent migration in another patient. In the case of stent migration, the stent required immediate removal, and the patient experienced no adverse consequences. The remaining patients tolerated the stent well, and all experienced subjective symptomatic relief. There were no stent-related deaths. The average duration of a stent after placement was 133 days. The median time of survival following stent insertion was 181 days. Forty-five percent of all patients died at 3 months, and 72% died at 6 months. CONCLUSION: The Dumon Y-stent proved to be useful and was well-tolerated in the management of malignant disease involving the main carina. It also provided successful palliation in patients with malignant tracheoesophageal fistulas.
OBJECTIVE: To study the efficacy of symptom relief and the safety of the Dumon Y-stent for central airway obstruction in malignant main carinal involvement and in malignant tracheoesophageal fistulas. DESIGN: A retrospective review. SETTING: Thoracic endoscopy referral center. PATIENTS AND METHODS: The medical records of 86 patients who had undergone the placement of a Dumon Y-stent at our institution were reviewed and analyzed. RESULTS: Ninety Dumon Y-stents were placed in 86 patients to relieve symptoms of dyspnea, cough, and/or hemoptysis. Four of these patients required removal of that stent and replacement with a longer Dumon Y-stent due to tumor progression. There were only two instances of procedure-related adverse effects, which included coughing following stent placement lasting 1 week in one patient and stent migration in another patient. In the case of stent migration, the stent required immediate removal, and the patient experienced no adverse consequences. The remaining patients tolerated the stent well, and all experienced subjective symptomatic relief. There were no stent-related deaths. The average duration of a stent after placement was 133 days. The median time of survival following stent insertion was 181 days. Forty-five percent of all patients died at 3 months, and 72% died at 6 months. CONCLUSION: The Dumon Y-stent proved to be useful and was well-tolerated in the management of malignant disease involving the main carina. It also provided successful palliation in patients with malignant tracheoesophageal fistulas.
Authors: Stefan Hoschek; Ursula Hoschek-Risslegger; Michael Fiegl; August Zabernigg; Georg Pall; Thomas Auberger; Eberhard Gunsilius; Thomas Schmid; Herbert Jamnig; Wolfgang Hilbe Journal: Wien Klin Wochenschr Date: 2007 Impact factor: 1.704
Authors: Seth J Rotz; Francisco A Almeida; Shlomo Koyfman; Sudhir Krishnan; Guramrinder Singh Thind; William Phillips; James Yun; Anthony Zembillas; Mark Zahniser; Alejandro Bribriesco Journal: Pediatr Blood Cancer Date: 2020-07-16 Impact factor: 3.167
Authors: Hans J Lee; Wassim Labaki; Diana H Yu; Benjamin Salwen; Christopher Gilbert; Andrea L C Schneider; Ricardo Ortiz; David Feller-Kopman; Sixto Arias; Lonny Yarmus Journal: J Thorac Dis Date: 2017-11 Impact factor: 2.895